Lv2
158 积分 2024-10-25 加入
Abbreviations
2个月前
已完结
Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China
2个月前
已完结
Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe
3个月前
已关闭
Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States
3个月前
已完结
Cost–Effectiveness Analysis of Nivolumab Plus Cabozantinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma
3个月前
已完结
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States
3个月前
已完结
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
3个月前
已完结
Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost‐effectiveness analysis in the United States and in China
3个月前
已完结
Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma
3个月前
已完结
Cost‐effectiveness of first‐line systemic therapies for unresectable hepatocellular carcinoma
3个月前
已完结
皖公网安备34019202002308
